oral semaglutide phase 3 oasis-1 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, trial oasis-1 oral semaglutide 50 mg – ACHIEVE-3: Orforglipron Superior to Semaglutide

Whole-wheat, chickpea, or lentil pasta varieties contain 34 more fiber than refined white pasta, enhancing satiety

This trial demonstrated that Retatrutide simultaneously addressed multiple health complications: participants experienced dramatic reductions in knee osteoarthritis pain (75.8% improvement), significant drops in blood pressure (14 mmHg systolic), and improvements in cardiovascular risk markers

treating or preventing binge eating disorder, bulimia nervosa, and/or obesity induced by administration of an antipsychotic or a steroid

Regular medication reviews in the first three months help assess efficacy, tolerability, and identify any problematic side effects early